Abstract
Objective. To assess the accuracy and patient compliance in using a novel home blood pressure monitoring device in high-risk pregnancy. Methods. Device accuracy was assessed according to the British Hypertension Society protocol in 45 pregnant women, including 15 with preeclampsia. Twenty-one high-risk pregnant women used the device in addition to their antenatal care. Results. The device achieved a mean difference ± SD of 0.4 ± 7.3/−0.4 ± 5.5 mmHg (pregnancy) and −2.6 ± 7.0/0.8 ± 4.4 mmHg (preeclampsia) for systolic/diastolic pressure. Eighty-one percent of women did at least 6 measurements/day and all women did at least 2 measurements/week. Conclusion. The Microlife WatchBP Home is accurate for use in pregnancy and increases surveillance in compliant patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
